The results of the international, randomized, open-label, phase 3 KEYNOTE-024 trial showed that, in patients with advanced NSCLC and programmed cell death ligand-1 (PD-L1) expression levels ≥50% in tumor cells, treatment with pembrolizumab was associated with significantly longer progression-free survival (PFS) and overall survival (OS), and fewer adverse events versus platinum-based chemotherapy [1, 6]. The gene discussed is CD274; the disease is neoplasm.